An interventional study of Cataract surgery and Eyedeal® Model PX65AS1 IOL in Lens Implantation, Intraocular, sponsored by Xi'an Eyedeal Medical Technology Co., Ltd. Recruiting at 2 sites in 2 countries. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2024-02-02.
Sponsored by Xi'an Eyedeal Medical Technology Co., Ltd · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 61 studies in Cataract with a site in Germany — 8 open to participants now, 11 under way, none of them phase 3. Cataract · Germany.
Among the 61 studies in Cataract with a site in Germany, this one is the 24th largest by planned enrollment of the 50 interventional ones that give a count, is one of 5 that started in 2023, is one of 35 with no phase, reaches primary completion later than 1 of the 10 other live ones, and was the 49th registered.
1,633 studies on the registry are indexed under Cataract; 234 are open to participants now.
Browse Cataract studies →8 of the 61 studies in Cataract with a site in Germany are open now. Recruiting first, the newest first:
Carl Zeiss Meditec AG · Sites in Germany, Czechia, Spain and 1 more country
Ages 18+
University of Cologne · Sites in Germany, Denmark, Netherlands and 1 more country
Ages 18+
University Hospital Augsburg · Sites in Germany
Ages 18+ · Healthy volunteers
Hanita Lenses · Sites in Germany
Ages 18+
Cristalens Industrie · Sites in Germany
Ages 50–85
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 143 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.
This study: 22 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 97 is above the median of 79 across 1,094 interventional studies indexed under Cataract.
Median enrollment 95 across the 50 interventional studies, 242 across the 11 observational. Of the 47 that completed or were terminated, 6 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
48 of 61 have an industry lead sponsor. The 10 most frequent:
Xi'an Eyedeal Medical Technology Co., Ltd is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Xi'an Eyedeal Medical Technology Co., Ltd has 2 studies filed under Cataract — fewer than ten, so there is no comparison to draw.
1 of the studies in Cataract with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07232615Biotech Healthcare Holding GmbhA Planned Study at Multiple Sites is Being Done to Compare the Results of Two Types of Trifocal Toric Intraocular Lenses Used in Cataract Surgery | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 61 studies in Cataract with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A cataract is the clouding of the natural lens in the eye and is very common as when getting older. A cloudy lens makes it difficult to see. A cataract is treated by removing the cloudy lens and replacing it with an intraocular lens (known as an IOL). The goal of this clinical trial is to determine if the Eyedeal® IOL can be safely implanted in a subject's eye and if it can replace efficiently the natural lens.
Subjects will be asked to attend a total of seven visits for this study for a period of 12 months after surgery.
To investigate the safety and performance of the Eyedeal® PX65AS1 intraocular lens (IOL)
The Eyedeal® IOL (PX65AS1) is a foldable single-piece ultra-violet absorbing posterior chamber intraocular lens (IOL). It is an optical implant to replace the human crystalline lens in the visual correction of aphakia in adult patients after cataract removal. The Eyedeal® PX65AS1 IOL lens is made of a high refractive index soft cross-linked polyolefin. The Eyedeal® PX65AS1 IOL lens has an aspheric optic with symmetric optic design and spherical neutral and correct lens's own spherical aberration supporting haptics to provide proper position of the IOL optic within the capsule.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eyedeal® Model PX65AS1 IOL
Procedure: Cataract surgery · Device: Eyedeal® Model PX65AS1 IOL
Subjects will undergo surgery to remove cataract (the cloudy lenses) via phacoemulsification, and implant the Eyedeal® Model PX65AS1 IOL in the eye capsule.
Subjects will undergo surgery to remove cataract (the cloudy lenses) via phacoemulsification, and implant the Eyedeal® Model PX65AS1 IOL in the eye capsule.
EFFICACY OUTCOME MEASURE - Uncorrected Distance Visual Acuity
Uncorrected distance Visual Acuity is measured in accordance with ISO 11979-7:2018 - Appendix E: BCVA 20/40 or better in 95% of cases. The stability and consistency of visual results will be measured over time.
Time frame: 12 months
SAFETY OUTCOME MEASURE - Best Corrected Visual Acuity
The safety of the Eyedeal® Model PX65AS1 IOLs (Xi'an Eyedeal Medical Technology Co., Ltd.) will be measured by the following criteria: Loss of BCDVA measured in accordance with ISO 11979-7:2018-Appendix E
Time frame: 12 months
SAFETY OUTCOME MEASURE - Evaluation of Patient record
The safety of the Eyedeal® Model PX65AS1 IOLs (Xi'an Eyedeal Medical Technology Co., Ltd.) will be measured by the following criteria: Patient record of inflammation, discomfort, or pain following surgery related to the Eyedeal® Model PX65AS1 IOL (Xi'an Eyedeal Medical Technology Co., Ltd.) . .
Time frame: 12 months
SAFETY OUTCOME MEASURE - Evaluation of Adverse Events
The safety of the Eyedeal® Model PX65AS1 IOLs (Xi'an Eyedeal Medical Technology Co., Ltd.) will be measured by the following criteria: Evaluation of all adverse events, adverse device effects and device deficiencies at post-operative examinations
Time frame: 12 months
Started Nov 2023 (actual). Primary completion is estimated for Feb 2025, 15 months after the start.
Of 190 industry-sponsored interventional studies with no phase under Cataract, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 28. This study's planned 15 months is close to that.
Counting every sponsor, half of 494 studies reached it within 17 months; a quarter within 9 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Xi'an Eyedeal Medical Technology Co., Ltd